OptimizeRx OPRX 深 沪
等待开盘 10-20 09:30:00 美东时间
8.74
+0.240
+2.82%
华盛通- 最 高8.90
- 今 开8.40
- 成交量 13.06万股
- 最 低 8.40
- 昨 收 8.50
- 总市值 1.65亿
- 52周最高 22.25
- 市盈率 静 32.36
- 换手率 0.69%
- 52周最低 4.54
- 委 比 -48.98%
- 总股本 1883.60万
- 历史最高 99.178
- 量 比 1.03
- 振 幅 5.88%
- 历史最低 3.78
- 每 手 1
- 风险率 4.06%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多美股大行评级 | 潜在涨幅11184.05%！如瑞迪博士获花旗上调目标价至1450美元，维持"买入"评级
今日重点评级关注：花旗：上调如瑞迪博士"买入"评级，目标价从1040美元升至1450美元；加拿大帝国商业银行：维持Inventiva"买入"评级，目标价从20美元升至21美元
09-30 08:33
B. Riley Securities Maintains Buy on OptimizeRx, Raises Price Target to $11
B. Riley Securities analyst Anderson Schock maintains OptimizeRx (NASDAQ:OPRX) with a Buy and raises the price target from $10 to $11.
09-29 23:42
OptimizeRx Expands Natural Language Audience Builder to Unify HCP and DTC Audience Intelligence
OptimizeRx Corp. has enhanced its AI-powered Natural Language Audience Builder (NLAB) tool, integrating Micro-Neighborhood Targeting (MNT) to enable media planners to create both HCP and DTC audiences in a single workflow. This update includes features like decile-based audience quality breakdowns and media channel propensities, improving precision and efficiency. MNT uses de-identified data for hyperlocal, privacy-safe targeting, benefiting non-...
09-14 12:00
OptimizeRx Earnings Call Balances Setbacks and Recovery
Optimizerx Corporation (($OPRX)) has held its Q2 earnings call. Read on for the...
08-21 08:23
美股大行评级 | 富国上调闪迪目标价从1400美元升至1550美元；塔吉特、Workday、应用材料等获多家大行上调目标价
今日重点评级关注：富瑞：维持ProMIS Neurosciences"买入"评级，目标价从69美元升至100美元；Benchmark：维持Cineverse"买入"评级，目标价从12美元升至14美元
08-17 13:37
Citizens Maintains Market Outperform on OptimizeRx, Raises Price Target to $11
Citizens analyst Constantine Davides maintains OptimizeRx (NASDAQ:OPRX) with a Market Outperform and raises the price target from $9 to $11.
08-14 20:58
OptimizeRx (OPRX) 2026财年第二季度财报电话会议：营收下降30%，重申业绩指引
OptimizeRx 2026财年第二季度营收下降30%至2050万美元，而管理层重申了其9500万至1亿美元的全年营收指引。
08-14 08:33
OptimizeRx Affirms FY2026 Sales Guidance of $95.000M-$100.000M vs $97.427M Est
OptimizeRx (NASDAQ:OPRX) affirms FY2026 sales outlook from $95.000 million-$100.000 million to $95.000 million-$100.000 million vs $97.427 million estimate.
08-13 04:22
OptimizeRx Announces Finance Leadership Appointments to Support the Next Phase of Growth
OptimizeRx Corp. announced leadership changes in its finance team. Andy D’Silva will become Chief Financial Officer and Heather Favazza will serve as Chief Accounting Officer, both effective January 1, 2027. Ed Stelmakh, the current CFO, will transition to a Strategic Advisor role through 2027 to ensure a smooth transition. Stelmakh has significantly contributed to the company’s financial growth and succession planning over the past five years. T...
08-12 20:05
OptimizeRx Rolls Out CopayCue To Provide Enhanced Brand Savings For Physicians
OptimizeRx Corp. (the "Company") (Nasdaq: OPRX), a leading provider of healthcare technology solutions helping life sciences companies reach and engage healthcare professionals (HCPs) and patients at the most important decision points, today announced the launch of CopayCue™, designed to make brand ...
06-30 19:38
